Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» GLP-1 agonist
GLP-1 agonist
How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
Yahoo Finance
Tue, 04/30/24 - 08:56 am
Novo Nordisk
Eli Lilly
earnings
obesity
weight loss
GLP-1 agonist
Ozempic
Wegovy
Zepbound
Mounjaro
Key opinion leaders on GLP-1 receptor agonist clinical trial design
Clinical Trials Arena
Fri, 04/26/24 - 11:41 am
clinical trials
GLP-1 agonist
type 2 diabetes
obesity
GLP-1s Like Novo Nordisk’s Ozempic Do Not Increase Thyroid Cancer Risk: Study
BioSpace
Wed, 04/10/24 - 09:48 am
Novo Nordisk
Ozempic
Victoza
GLP-1 agonist
thyroid cancer
Parkinson’s disease may be helped by GLP-1 drug, new study finds
Stat
Wed, 04/3/24 - 10:41 pm
GLP-1 agonist
Parkinson's Disease
lixisenatide
Top U.S. addiction researcher calls GLP-1 data for addiction ‘very, very exciting’
Stat
Thu, 03/21/24 - 06:43 pm
GLP-1 agonist
addiction
GLP-1s set to take drug sales throne from PD-1 inhibitors in 2024
Medical Marketing and Media
Wed, 03/20/24 - 09:43 pm
GLP-1 agonist
PD-1 inhibitors
Wegovy
Ozempic
Zepbound
Mounjaro
Eli Lilly strikes deal with Amazon: Will the ecommerce giant become go-to destination for GLP-1s?
Biopharma Reporter
Mon, 03/18/24 - 11:02 am
Eli Lilly
Novo Nordisk
GLP-1 agonist
Zepbound
Wegovy
Amazon
Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity
Drugs.com
Sun, 03/10/24 - 08:28 pm
Regor Therapeutics
clinical trials
GLP-1 agonist
RGT-075
obesity
Americans don't think weight-loss drugs will fix the obesity epidemic
Axios
Wed, 02/28/24 - 10:44 am
obesity
weight loss
Ozempic
Wegovy
Zepbound
GLP-1 agonist
GLP1ra’s beyond obesity and diabetes: Is the sky the limit?
Clinical Trials Arena
Mon, 02/26/24 - 11:03 am
GLP-1 agonist
Wegovy
Zepbound
Weight-loss drugs could boost US GDP by 1% in coming years, Goldman says
Reuters
Thu, 02/22/24 - 11:14 pm
obesity
weight loss
GLP-1 agonist
Novo Nordisk
Eli Lilly
Opioid cravings were reduced by anti-obesity drug in small study
Stat
Sun, 02/18/24 - 08:29 pm
GLP-1 agonist
opioids
opioid addiction
clinical trials
Weight-loss drugs tied to benefit after hip replacement
Reuters
Mon, 02/12/24 - 10:26 am
hip replacements
GLP-1 agonist
Ozempic
Novo Nordisk
COVID-19 Cliff and Skyrocketing GLP-1 Drug Sales Highlight Q4 2023 Earnings
BioSpace
Sun, 02/11/24 - 03:50 pm
earnings
COVID-19
GLP-1 agonist
JNJ
Bristol Myers Squibb
Pfizer
AstraZeneca
Sanofi
Eli Lilly
Novo Nordisk
Obesity drug mania takes over Amgen’s earnings call
BioPharma Dive
Wed, 02/7/24 - 09:17 pm
Amgen
earnings
GLP-1 agonist
obesity
AMG-133
Researchers probe new uses of popular weight loss, diabetes drugs
Beckers Hospital Review
Tue, 01/16/24 - 09:08 am
GLP-1 agonist
Ozempic
Mounjaro
Wegovy
Novo Nordisk
Eli Lilly
JPM2024: Lilly CEO David Ricks Weighs In on GLP-1s and AI
BioSpace
Mon, 01/15/24 - 09:43 am
JPMHC 2024
Eli Lilly
David Ricks
artificial intelligence
GLP-1 agonist
FDA says no evidence yet linking weight loss drugs to suicidal thoughts
Reuters
Thu, 01/11/24 - 11:35 am
Novo Nordisk
Eli Lilly
weight loss
GLP-1 agonist
FDA
Ozempic not tied to pancreatic cancer risk, study suggests
Beckers Hospital Review
Tue, 01/9/24 - 10:04 pm
Ozempic
Trulicity
type 2 diabetes
Novo Nordisk
GLP-1 agonist
pancreatic cancer
AI, Neuroscience and GLP-1s Will Maintain Momentum: Expert Panel
BioSpace
Tue, 01/9/24 - 10:00 pm
biotech
artificial intelligence
GLP-1 agonist
Neuroscience
Pages
1
2
3
4
next ›
last »